PortalPublikationenAnabolic Therapies in Osteoporosis and Bone Regeneration

Anabolic Therapies in Osteoporosis and Bone Regeneration

Standard

Anabolic Therapies in Osteoporosis and Bone Regeneration. / Russow, Gabriele; Jahn, Denise; Appelt, Jessika; Märdian, Sven; Tsitsilonis, Serafeim; Keller, Johannes.

in: INT J MOL SCI, Jahrgang 20, Nr. 1, 26.12.2018.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Russow, G, Jahn, D, Appelt, J, Märdian, S, Tsitsilonis, S & Keller, J 2018, 'Anabolic Therapies in Osteoporosis and Bone Regeneration', INT J MOL SCI, Jg. 20, Nr. 1. https://doi.org/10.3390/ijms20010083

APA

Russow, G., Jahn, D., Appelt, J., Märdian, S., Tsitsilonis, S., & Keller, J. (2018). Anabolic Therapies in Osteoporosis and Bone Regeneration. INT J MOL SCI, 20(1). https://doi.org/10.3390/ijms20010083

Vancouver

Russow G, Jahn D, Appelt J, Märdian S, Tsitsilonis S, Keller J. Anabolic Therapies in Osteoporosis and Bone Regeneration. INT J MOL SCI. 2018 Dez 26;20(1). https://doi.org/10.3390/ijms20010083

Bibtex

@article{e1c35359f3b44065a4fb1a8cda02deeb,
title = "Anabolic Therapies in Osteoporosis and Bone Regeneration",
abstract = "Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.",
keywords = "Anabolic Agents/therapeutic use, Antibodies, Neutralizing/therapeutic use, Bone Morphogenetic Proteins/immunology, Bone Regeneration/physiology, Fractures, Bone/drug therapy, Humans, Osteoporosis/drug therapy, Parathyroid Hormone/therapeutic use, Receptor Activator of Nuclear Factor-kappa B/metabolism, Wnt Signaling Pathway",
author = "Gabriele Russow and Denise Jahn and Jessika Appelt and Sven M{\"a}rdian and Serafeim Tsitsilonis and Johannes Keller",
year = "2018",
month = dec,
day = "26",
doi = "10.3390/ijms20010083",
language = "English",
volume = "20",
journal = "INT J MOL SCI",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

RIS

TY - JOUR

T1 - Anabolic Therapies in Osteoporosis and Bone Regeneration

AU - Russow, Gabriele

AU - Jahn, Denise

AU - Appelt, Jessika

AU - Märdian, Sven

AU - Tsitsilonis, Serafeim

AU - Keller, Johannes

PY - 2018/12/26

Y1 - 2018/12/26

N2 - Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.

AB - Osteoporosis represents the most common bone disease worldwide and results in a significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the development of osteoporosis are also associated with delayed fracture healing and impaired bone regeneration. Based on a steadily increasing life expectancy in modern societies, the global implications of osteoporosis and impaired bone healing are substantial. Research in the last decades has revealed several molecular pathways that stimulate bone formation and could be targeted to treat both osteoporosis and impaired fracture healing. The identification and development of therapeutic approaches modulating bone formation, rather than bone resorption, fulfils an essential clinical need, as treatment options for reversing bone loss and promoting bone regeneration are limited. This review focuses on currently available and future approaches that may have the potential to achieve these aims.

KW - Anabolic Agents/therapeutic use

KW - Antibodies, Neutralizing/therapeutic use

KW - Bone Morphogenetic Proteins/immunology

KW - Bone Regeneration/physiology

KW - Fractures, Bone/drug therapy

KW - Humans

KW - Osteoporosis/drug therapy

KW - Parathyroid Hormone/therapeutic use

KW - Receptor Activator of Nuclear Factor-kappa B/metabolism

KW - Wnt Signaling Pathway

U2 - 10.3390/ijms20010083

DO - 10.3390/ijms20010083

M3 - SCORING: Review article

C2 - 30587780

VL - 20

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 1

ER -